Nasdaq btai.

BioXcel Therapeutics Inc (NASDAQ:BTAI) shares fell almost 35% after it reported a revenue miss and greater than forecast loss for the third quarter. The New Haven, Connecticut-based biopharmaceutical company reported sales of $341,000, up from $137,000 in the year-ago quarter but below estimates of $840,000.BioXcel Therapeutics, Inc. Common Stock (BTAI) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics Stock (NASDAQ:BTAI), Short Interest Report. Short interest for BioXcel Therapeutics gives investors a sense of the degree to which investors are betting on the decline of ...

BioXcel Therapeutics (NASDAQ:BTAI) fell ~58% pre-market Thursday even after announcing that its Phase 3 trial for Alzheimer’s candidate BXCL501 reached its main goal as investors reacted to its ...

This forecast implies upside of 128%. Thus, BTAI could be one of the best short-squeeze stocks. Aravive (ARAV) Source: Epic Cure / Shutterstock. Hailing from Houston, Texas, Aravive (NASDAQ:ARAV) ...BTAI - BioXcel Therapeutics Inc (NASDAQ) Stock - Earnings History. BioXcel Therapeutics Inc. SHARE PRICE. EXTENDED. Day's Range, -. 52 Week Range, -.

BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ...Philadelphia, Pennsylvania--(Newsfile Corp. - November 29, 2023) - A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain ...Get a brief overview of BioXcel Therapeutics, Inc. financials with all the important numbers. View the latest BTAI income statement, balance sheet, and financial ratios.BTAI BTAI AFTER HOURS QUOTE BTAI LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...Nov 14, 2022 · By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Commercial Day Highlights Positive Early Launch Metrics for IGALMI™ On October 18, 2022, BioXcel Therapeutics ...

BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

BioXcel Therapeutics, Inc. (BTAI) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.9000 +0.0700 (+1.83%) At close: 04:00PM EST 3.9999 +0.10 …

BTAI BioXcel Therapeutics Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... CT 06511 | www.bioxceltherapeutics.com September 2022 AI-Driven Drug Development in Neuroscience and Immuno-oncology NASDAQ: BTAI This presentation includes "forward-looking state 2022-09-12 - 2 viewsBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ...Good news is that we have both equity as well as potential debt option in addition to, as I mentioned previously, partnering, which can be outside the U.S. for Alzheimer’s-related agitation ...Nov 25, 2023 · Isaac Mitchell. November 25, 2023. Technologies. BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.78. At the close of trading, the stock’s price was $4.00, to imply an increase of 4.44% or $0.17 in intraday trading. The BTAI share’s 52-week high ... Over the past 3 months, 10 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Following a 60% decline over last year, recent gains may please BioXcel Therapeutics, Inc. (NASDAQ:BTAI) institutional owners Read full article [email protected] (Simply Wall St)

Jun 29, 2023 · BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today ... BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) – Equities research analysts at HC Wainwright reduced their FY2023 EPS estimates for BioXcel Therapeutics in a research note issued to investors on Wednesday, November 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($6.63) per share for the year, down from […]BioXcel Therapeutics will host a conference call and webcast at 8:30 a.m. ET on March 9 to discuss its fourth quarter and full-year 2022 financial results and provide an update on recent ...4 Jul 2023 ... Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy ...NEW HAVEN, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...Headline. BioXcel Therapeutics, Inc. Forecasted to Post FY2023 Earnings of ($6.63) Per Share (NASDAQ:BTAI) americanbankingnews.com - November 18 at 1:48 AM. BioXcel Therapeutics (NASDAQ:BTAI) Stock Rating Reaffirmed by HC Wainwright. americanbankingnews.com - November 17 at 4:12 AM. BTAI: Alignment with FDA on At-Home Study of BXCL501 in ...

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...View the latest BioXcel Therapeutics Inc. (BTAI) stock price, news, historical charts, analyst ratings and financial information from WSJ.

BioXcel Therapeutics, Inc. Common Stock (BTAI) Nasdaq Listed. DATA AS OF Nov 12, 2021. 0. Add to Watchlist.Nov 30, 2023 · The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023. The analyst firm set a price target for 11.00 expecting BTAI ... The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91.NasdaqCM:BTAI Earnings and Revenue Growth July 8th 2021. Hedge funds don't have many shares in BioXcel Therapeutics. Our data shows that BioXcel Corporation is the largest shareholder with 31% of ...Find the latest Insider Activity data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...Jun 2, 2023 · Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 586.04% Upside. As of ... NEW HAVEN, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on November 15, 2023.The analyst firm set a price target for $11.00 expecting BTAI to rise to ...

Nov 14, 2022 · By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Commercial Day Highlights Positive Early Launch Metrics for IGALMI™ On October 18, 2022, BioXcel Therapeutics ...

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BTAI technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of BioXcel Therapeutics, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more.BTAI BioXcel Therapeutics Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... CT 06511 | www.bioxceltherapeutics.com September 2022 AI-Driven Drug Development in Neuroscience and Immuno-oncology NASDAQ: BTAI This presentation includes "forward-looking state 2022-09-12 - 2 viewsNov 14, 2023 · BioXcel Therapeutics (NASDAQ:BTAI) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. BioXcel ... The SEC requires all publicly traded companies, foreign and domestic, to disclose financial condition, operating results, management compensation, and other ...We would like to show you a description here but the site won’t allow us.NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for BTAI stock stock is $12.2, which predicts an increase of 213.62%. The lowest target is $4.00 and the highest is $22. …

BioXcel Therapeutics, Inc. (BTAI) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.9000 +0.0700 (+1.83%) At close: 04:00PM EST 3.9999 +0.10 …BioXcel Therapeutics (NASDAQ:BTAI) announces that the FDA has accepted for filing the New Drug Application (NDA) for BXCL501, an investigational, orally dissolving thin film formulation of ...The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 …Instagram:https://instagram. dhhortonbuzz feed stockstocks vs options vs futurestop emerging markets etf Shares of the commercial-stage biopharma BioXcel Therapeutics ( BTAI 16.29%) were up by 10.3% on heavy volume as of 3:29 p.m. ET Monday afternoon. The big gain came after the drugmaker reported ... reit with high dividendbest discount dental plans 25 May 2023 ... Healthcare Stocks on the Move Thursday: ELEV, CDIO, HSCS, XBIT, ANNX, BIOC, BTAI, BHG · These Healthcare stocks are trading higher: · These ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today ... ameritrade forex leverage Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ... Find the latest Earnings Report Date for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.